Therapeutic peptides and methods for treating autoimmune related disease
Abstract
Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and/or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFγ, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . A method for one or more of preventing, modulating, reducing, treating, or reversing type 2 diabetes in a subject, comprising
administering to a subject having type 2 diabetes; a therapeutically effective amount of a peptide that affects the interaction of CD40 with CD154/CD40-ligand.
53 . The method of claim 52 , the peptide binding to CD40.
54 . The method of claim 52 , said peptide binding to a CD40 protein with a Kd of greater than 10 −6 .
55 . The method of claim 52 , said peptide affecting the interaction of CD40 and CD154.
56 . The method of claim 52 , said peptide inhibiting the binding of CD40 to CD154.
57 . The method of claim 52 , said peptide binding CD40 at the site where CD40 interacts with CD154.
58 . The method of claim 52 , said peptide affecting the interaction of CD40 with CD154 to prevent the expansion of Th40 cells.
59 . The method of claim 52 , said peptide affecting the interaction of CD40 with CD154 reduce the number of Th40 cells.
60 . The method of claim 52 , said peptide affecting the interaction of CD40 with CD154 to alter the cytokine expression profile of a cell population treated with said peptide.
61 . The method of claim 52 , said peptide affecting an amino acid sequence selected from the group of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:27.
62 . (canceled)
63 . The method of claim 52 , said peptide being an amino acid sequence selected from the group of SEQ ID NO:4-9 and 24-30.
64 . (canceled)
65 . (canceled)
66 . The method of claim 52 , the peptide interacting with the CD40 protein to modulate glucose transport protein 4 (GLUT 4).
67 . (canceled)
68 . (canceled)
69 . The method of claim 52 , said peptide binding to multiple bone marrow derived cell types which express CD40 of approximately 45 kDa, including splenic CD4hi cells, CD8 cells, and other antigen presenting cells.
70 . (canceled)
71 . A method of modulating type 2 diabetes in a patient comprising
administering to a patient a peptide that binds to a CD40 protein at the CD154-binding site and modulates type 2 diabetes.
72 . (canceled)
73 . (canceled)
74 . The method of claim 71 , further comprising, administering to the subject, a peptide that interacts with a CD40 protein to modulate IFNγ.
75 . The method of claim 71 , the peptide being selected from SEQ ID NOs 3-9 and 27-30.
76 . The method of claim 71 , further comprising administering a peptide selected from SEQ ID NOs 3-9 and 27-30, in an amount sufficient to reduce or inhibit interleukin-2 signaling.
77 . The method of claim 71 , further comprising administering a peptide selected from SEQ ID NOs 3-9 and 27-30, in an amount sufficient to reduce or inhibit interleukin 17 (IL-17) signaling.
78 . (canceled)
79 . (canceled)
80 . (canceled)
81 . A method to one or more of prevent, modulate, or reduce type 2 diabetes, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a peptide which specifically binds to a CD40 presenting cells at the CD154 binding site.
82 . (canceled)
83 . (canceled)
84 . (canceled)
85 . (canceled)
86 . (canceled)
87 . (canceled)
88 . (canceled)
89 . (canceled)
90 . The method of claim 81 , said peptide comprising an amino acid sequence selected from the group of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30.
91 . (canceled)
92 . (canceled)
93 . (canceled)
94 . (canceled)
95 . (canceled)
96 . (canceled)
97 . (canceled)
98 . (canceled)
99 . (canceled)
100 . (canceled)
101 . (canceled)
102 . (canceled)
103 . (canceled)
104 . (canceled)
105 . (canceled)
106 . (canceled)
107 . (canceled)
108 . (canceled)
109 . (canceled)
110 . (canceled)
111 . (canceled)
112 . (canceled)
113 . (canceled)
114 . (canceled)Join the waitlist — get patent alerts
Track US2019263888A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.